Toshiki Sudo

Summary

Affiliation: Otsuka Pharmaceutical Co
Country: Japan

Publications

  1. ncbi Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
    T Sudo
    Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan
    Biochem Pharmacol 59:347-56. 2000
  2. ncbi Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method
    T Sudo
    Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co, Ltd, 463 10 Kagasuno, Kawauchi cho, Tokushima 771 0192, Japan
    Br J Pharmacol 133:1396-404. 2001
  3. ncbi Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure method
    Toshiki Sudo
    First Institute of New Drug Research, Otsuka Pharmaceutical Co, Ltd 463 10, Kagasuno, Kawauchi cho, Tokushima 771 0192, Japan
    Platelets 14:239-46. 2003
  4. ncbi Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets
    Toshiki Sudo
    First Institute of New Drug Research, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan
    Platelets 14:381-90. 2003
  5. ncbi Genetic strain differences in platelet aggregation of laboratory mice
    Toshiki Sudo
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Kawauchi cho, Tokushima 771 0192, Japan
    Thromb Haemost 95:159-65. 2006
  6. ncbi Genetic strain differences in platelet aggregation and thrombus formation of laboratory rats
    Toshiki Sudo
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co Ltd, 463 10 Kagasuno, Tokushima, Japan
    Thromb Haemost 97:665-72. 2007
  7. ncbi Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets
    Hideki Hayashi
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Kawauchi cho, Tokushima, 771 0192, Japan
    Thromb Haemost 102:327-35. 2009
  8. ncbi Identification of the active region responsible for the anti-thrombotic activity of anopheline anti-platelet protein from a malaria vector mosquito
    Hideki Hayashi
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Company Limited, Tokushima, Japan
    Platelets 24:324-32. 2013
  9. ncbi Anopheline anti-platelet protein from a malaria vector mosquito has anti-thrombotic effects in vivo without compromising hemostasis
    Hideki Hayashi
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Company Limited, Tokushima, Japan
    Thromb Res 129:169-75. 2012
  10. ncbi Lactoferrin inhibits platelet production from human megakaryocytes in vitro
    Kuniko Matsumura-Takeda
    Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1 78 1 Sho machi, Tokushima 770 8505, Japan
    Biol Pharm Bull 31:569-73. 2008

Detail Information

Publications14

  1. ncbi Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
    T Sudo
    Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan
    Biochem Pharmacol 59:347-56. 2000
    ..998). These data demonstrated that OPC-33540 is a highly selective and potent PDE3 inhibitor and a useful probe for identification of the intracellular functions of PDE3...
  2. ncbi Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method
    T Sudo
    Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co, Ltd, 463 10 Kagasuno, Kawauchi cho, Tokushima 771 0192, Japan
    Br J Pharmacol 133:1396-404. 2001
    ..4. These results demonstrate that the SFP aggregometer can sensitively detect anti-platelet aggregatory effects of various kinds of drugs. So that it is a useful tool for evaluation of anti-platelet drugs...
  3. ncbi Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure method
    Toshiki Sudo
    First Institute of New Drug Research, Otsuka Pharmaceutical Co, Ltd 463 10, Kagasuno, Kawauchi cho, Tokushima 771 0192, Japan
    Platelets 14:239-46. 2003
    ..These results demonstrated that species differences in laboratory animals exist for whole blood aggregation, and that the SFP aggregometer may be useful to evaluate platelet function in various animal species...
  4. ncbi Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets
    Toshiki Sudo
    First Institute of New Drug Research, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan
    Platelets 14:381-90. 2003
    ..The PKA/PKG inhibitor, H-89, inhibited VASP phosphorylation by cilostazol. These results demonstrated that cilostazol phosphorylates VASP through the PDE3 inhibition, increase of cAMP level, and PKA activation in platelets...
  5. ncbi Genetic strain differences in platelet aggregation of laboratory mice
    Toshiki Sudo
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Kawauchi cho, Tokushima 771 0192, Japan
    Thromb Haemost 95:159-65. 2006
    ..The present study demonstrated that there is considerable strain difference in platelet aggregation among laboratory mice, which should be taken into account in backcrossing knockout strains...
  6. ncbi Genetic strain differences in platelet aggregation and thrombus formation of laboratory rats
    Toshiki Sudo
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co Ltd, 463 10 Kagasuno, Tokushima, Japan
    Thromb Haemost 97:665-72. 2007
    ..The present study demonstrates that there are considerable strain differences in platelet aggregation among laboratory rats, which reflect thrombus formation...
  7. ncbi Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets
    Hideki Hayashi
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Kawauchi cho, Tokushima, 771 0192, Japan
    Thromb Haemost 102:327-35. 2009
    ..Our results provide new insights into the inhibitory effect of cAMP-elevating agents on platelet function...
  8. ncbi Identification of the active region responsible for the anti-thrombotic activity of anopheline anti-platelet protein from a malaria vector mosquito
    Hideki Hayashi
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Company Limited, Tokushima, Japan
    Platelets 24:324-32. 2013
    ..These results indicated that the essential moiety of AAPP for collagen binding and anti-thrombotic activity was in the region encoded by exon 3-4, which is highly conserved among the counterpart regions of other mosquito species...
  9. ncbi Anopheline anti-platelet protein from a malaria vector mosquito has anti-thrombotic effects in vivo without compromising hemostasis
    Hideki Hayashi
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Company Limited, Tokushima, Japan
    Thromb Res 129:169-75. 2012
    ..To examine the potential of AAPP as a therapeutic agent, we investigated the in vivo anti-thrombotic effects of AAPP...
  10. ncbi Lactoferrin inhibits platelet production from human megakaryocytes in vitro
    Kuniko Matsumura-Takeda
    Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1 78 1 Sho machi, Tokushima 770 8505, Japan
    Biol Pharm Bull 31:569-73. 2008
    ..In addition, it did not inhibit MK progenitors. These results suggest that LF directly inhibits PLT production from matured MKs, but does not inhibit megakaryopoiesis, including proliferation/maturation processes...
  11. ncbi Characterization of STZ-Induced Type 2 Diabetes in Zucker Fatty Rats
    Takashi Okamoto
    First Institute of New Drug Discovery, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan
    Exp Anim 57:335-45. 2008
    ..Metformin lowered the blood glucose levels of STZ-ZF rats in a dose-dependent manner. These results suggest that STZ-ZF rats are useful for studies of T2DM and for the evaluation of the efficacy of anti-diabetic drugs...
  12. ncbi Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice
    Ken ichi Aihara
    Department of Medicine and Bioregulatory Sciences and 21st Century Center of Excellence Program, The University of Tokushima Graduate School of Health Biosciences, Tokushima, Japan
    J Clin Invest 117:1514-26. 2007
    ....
  13. ncbi Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito
    Shigeto Yoshida
    Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical University, Tochigi, Japan
    Blood 111:2007-14. 2008
    ..Our study may provide important insights for elucidating the effects of mosquito blood feeding against host hemostasis...
  14. ncbi Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice
    Ken ichi Aihara
    Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Japan
    J Biol Chem 279:35798-802. 2004
    ..These results demonstrate that activation of nuclear VDR elicits antithrombotic effects in vivo, and suggest that the VDR system may play a physiological role in the maintenance of antithrombotic homeostasis...